[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"apple-watch\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:apple-watch":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100644448","wearable-assessment-of-thoracic-cardiac-health-and-exercise-performance-trial-prospective-100644448",false,"NCT07663799","Wearable Assessment of Thoracic, Cardiac Health and Exercise Performance Trial Prospective","Wearable Assessment of Thoracic, Cardiac Health and Exercise Performance Trial Prospective (WATCH-XP)","WATCH-XP","Inclusion Criteria:\n\n* Age 20 to 70 years old\n* Ability to provide informed consent\n* History of the following cardiovascular conditions:\n* Adult congenital heart disease\n* Pulmonary hypertension\n* Heart failure\n* Coronary artery disease\n* Athletes undergoing cardiovascular assessment\n\nExclusion Criteria:\n\n* Contraindication for undergoing physical exertion including cardio-pulmonary exercise testing (CPX) and 6-minute walk test (6MWT)\n* Pregnancy\n* Known allergy to components of the investigational product","ALL","20 Years","70 Years",{"count":21,"type":22},20,"ESTIMATED","OBSERVATIONAL","Wearable health technology, particularly smartwatches, has revolutionized personal health monitoring by enabling continuous, non-invasive tracking of various physiological parameters. The potential applications of these devices in cardiology are extensive, but it is crucial to validate their accuracy against established medical-grade devices.\n\nThe Apple Watch Series 9 (Apple, USA) exemplifies the capabilities of modern smartwatches, offering a wide range of health tracking features. These include heart rate monitoring, detection of irregular heart rhythms suggestive of atrial fibrillation, electrocardiogram recording, blood oxygen level measurement, and comprehensive mobility metrics (including VO2 max, six-minute walk distance, walking speed, step length, double support time, and walking asymmetry). Many of these parameters are highly relevant for cardiovascular patients, potentially aiding in disease progression monitoring and adverse event prediction. However, there is a lack of comprehensive validation studies for these devices in specific cardiovascular disease populations.\n\nThis investigator-initiated, prospective observational study will consist of two phases: a training phase which involves 50 participants and a prospective validation phase which involves 20 participants. The study aims to validate smartwatch-based assessments using medical-grade devices and techniques. The study will focus on adult patients with congenital heart disease, pulmonary hypertension, heart failure, and coronary artery disease, as well as athletes undergoing cardiovascular assessment. By comparing smartwatch data with established clinical measurements, we seek to determine the reliability and potential clinical utility of these wearable devices in diverse cardiovascular contexts. Anonymized smartwatch data collected during the two phases will be published to a publicly registry to facilitate further research. This research will help bridge the gap between consumer-grade wearable technology and clinical practice in cardiology.",[26,27,28,29,30],"Congenital Heart Disease","Pulmonary Hypertension","Heart Failure","Coronary Heart Disease (CHD)","Apple Watch",[32,33,34,35,36],"apple watch","congenital heart disease","heart failure","coronary heart disease","pulmonary hypertension","NOT_YET_RECRUITING","2026-06-16",{"date":40,"type":41},"2026-06-23","ACTUAL",{"date":43,"type":22},"2026-08-01",{"date":45,"type":22},"2028-12-31",{"name":47,"class":48},"The University of Hong Kong","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":61,"studyType":23,"phases":4,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":82},"100627382","ted-rogers-understanding-of-exacerbations-in-heart-failure-2-monitor-100627382","NCT07447908","Ted Rogers Understanding of Exacerbations in Heart Failure 2: Monitor","Ted Rogers Understanding of Exacerbations in Heart Failure 2 (TRUE-HF2): Observational Study","TRUE-HF 2","Inclusion Criteria:\n\n* broad age range (\\> 18 years of age)\n* NT-proBNP \\> 400 or 1000 if in AF\n* Within 3 months post discharge from HF hospitalization\u002F HF ED visit\u002F HF rapid clinic visit with intensification of diuretic therapy\n* NYHA functional class I-IV, heart failure with reduced and preserved ejection fraction\n* Literacy in English\n* Patient provided informed consent\n\nExclusion Criteria:\n\n* Unable to perform a CPET based on the standard protocol\n* End stage renal disease requiring dialysis\n* Living with LVAD\n* MRP deems patient unfit for the study\n* Post heart transplant","18 Years",{"count":60,"type":22},360,"1 Year","Heart Failure (HF) is a complex disease associated with the highest burden of cost to the healthcare system. The cardiopulmonary exercise test (CPET) is instrumental in determining the prognosis of patients with HF. This multicentre study will validate whether aggregate biometric data from the Apple Watch combined with demographic, cardiac, and biomarker testing can improve our ability to predict heart failure outcomes among a diverse outpatient HF population.",[28,64,65,66,30],"Heart Failure - NYHA II - IV","Heart Failure Patients","Cardiopulmonary Exercise Test",[30,68,28,69,70,71,72],"CPET","Artificial Intelligence","Wearable Technology","Wearable","Remote monitoring","2026-02-25",{"date":75,"type":41},"2026-03-04",{"date":77,"type":22},"2026-03-16",{"date":79,"type":22},"2029-09",{"name":81,"class":48},"University Health Network, Toronto",3]